Describes NIDA’s drug abuse and addiction research priorities for the use of the American Recovery and Reinvestment Act of 2009 funds.
Highlights a project in which nine research centers collaborate with criminal justice partners to test science-based tools for integrating drug abuse treatment in prisons and probation and parole programs.
Presents data on the length of stay in substance abuse treatment among people who were in treatment as a result of legal pressure as compared with those in treatment voluntarily.
Reports on an animal study showing that methadone, normally used as a therapy for opioid abuse, may prove to be an effective treatment for cocaine abuse.
Remembers Henry I. "Hank" Yamamura, an eminent neuropharmacologist who pioneered radioligand binding assays, contributing valuable knowledge about neurotransmitter transporters and receptors.
Reports on a link between mental disorders, including mood, anxiety, or personality disorder and nicotine dependence in pregnancy women.
Reports on study results indicating a medication prescribed for schizophrenia and manic phases of bipolar disorder shows promise as a cocaine addiction treatment.
Reports on a randomized controlled trial of HIV-infected men and women who, as a result of receiving selenium supplements, experienced lower HIV viral load and greater CD4 cell count.
Highlights NIDA-funded research to develop vaccines against addiction to drugs such as cocaine, nicotine, phencyclidine (PCP), and methamphetamine.
Highlights results from a pilot study suggesting that lofexidine, an anti-hypertensive medication, can enhance success rates among patients taking maintenance naltrexone to avoid opioid relapse.